Safety of Amiodarone and Ranolazine Together in Patients With Angina (SARA)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2012 by Cardiovascular Consultants of Nevada.
Recruitment status was  Recruiting
Gilead Sciences
Information provided by (Responsible Party):
Cardiovascular Consultants of Nevada Identifier:
First received: March 18, 2012
Last updated: March 20, 2012
Last verified: March 2012
Ranolazine is an effective and remarkably safe agent for the treatment of patients with chronic stable angina, but its inhibition of voltage gated potassium channels and electrocardiogram (EKG) corrected QT (QTc) prolongation properties have lead many to question its safety when combined with antiarrhythmic drugs. The investigators have proposed a study to determine the safety of ranolazine in patients with chronic stable angina who also take amiodarone. And are conducting a prospective single-center randomized single-blinded placebo controlled trial to run out of our large cardiology practice setting at Cardiovascular Consultants of Nevada. The hypothesis is that there will be no difference in the ventricular arrhythmia burden. The primary outcome will be the measurement of ventricular arrhythmia episodes on serial holter monitor and other serially acquired recordings (such as electrocardiogram, pacemaker or implantable defibrillator (ICD) data, and stress test data) over a three month trial period.

Condition Intervention Phase
Chronic Stable Angina
Coronary Artery Disease
Atrial Fibrillation
Ventricular Tachycardia
Drug: ranolazine
Drug: placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Official Title: Safety of Amiodarone and Ranolazine Together in Patients With Stable Angina

Resource links provided by NLM:

Further study details as provided by Cardiovascular Consultants of Nevada:

Primary Outcome Measures:
  • ventricular arrhythmia [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]
    primary outcome is the burden of ventricular arrhythmias measured on serial holter monitor recordings, stress test recordings, pacemaker or implantable defibrillator (ICD) recordings if available, at baseline and serially to trial completion.

Secondary Outcome Measures:
  • atrial arrhythmia burden [ Time Frame: 3 months ] [ Designated as safety issue: No ]
    burden of atrial arrhythmias will be measured on serial holter monitor recordings

  • Electrocardiogram (EKG) corrected QT (QTc) interval measurement [ Time Frame: over the 3 month trial ] [ Designated as safety issue: Yes ]
    The electrocardiogram (EKG) corrected QT (QTc) interval be quantitated at baseline and serially to trial completion

  • hospitalization [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]
    Hospitalization rates, if any, will be serially quantitated to trial completion

  • syncope hospitalization [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]
    syncope hospitalization rate quantitation to trial completion

  • liver function assay [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]
    serum liver function testing will be conducted at baseline and serially to trial completion

Estimated Enrollment: 50
Study Start Date: January 2012
Estimated Study Completion Date: July 2013
Estimated Primary Completion Date: April 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: sugar pill
one pill twice daily, uptitrated to two pills twice daily to mirror ranolazine prescription strategy
Drug: placebo
one pill twice daily, to increase to two pills twice daily to mirror standard ranolazine treatment strategy
Active Comparator: Ranolazine
500 mg twice daily, titrated to 1000 mg twice daily if needed for relief of anginal symptoms
Drug: ranolazine
ranolazine 500mg twice daily, may increase to 1000 mg twice daily for therapy optimization in treating chronic stable angina
Other Name: Ranexa


Ages Eligible for Study:   35 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • ischemic cardiac disease
  • chronic anginal symptoms
  • on amiodarone therapy for other cardiac conditions

Exclusion Criteria:

  • pregnant
  • non-English speaking
  • unstable angina
  • baseline electrocardiogram (EKG) corrected QT (QTc)>490ms
  • severe thyroid dysfunction
  • heart block without a pacer system
  • liver disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01558830

Contact: Erik J Sirulnick, MD 702-731-8224
Contact: Christie Abano, RN 702-731-8224

United States, Nevada
Cardiovascular Consultants of Nevada Recruiting
Henderson, Nevada, United States, 89052
Cardiovascular Consultants of Nevada Recruiting
Las Vegas, Nevada, United States, 89144
Cardiovascular Consultants of Nevada Recruiting
Las Vegas, Nevada, United States, 89196
Sponsors and Collaborators
Cardiovascular Consultants of Nevada
Gilead Sciences
Principal Investigator: Erik J SIrulnick, MD Cardiovascular Consultants of Nevada
  More Information

Responsible Party: Cardiovascular Consultants of Nevada Identifier: NCT01558830     History of Changes
Other Study ID Numbers: IN-US-259-0121 
Study First Received: March 18, 2012
Last Updated: March 20, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by Cardiovascular Consultants of Nevada:

Additional relevant MeSH terms:
Angina Pectoris
Angina, Stable
Atrial Fibrillation
Coronary Artery Disease
Coronary Disease
Myocardial Ischemia
Tachycardia, Ventricular
Arrhythmias, Cardiac
Arterial Occlusive Diseases
Cardiovascular Diseases
Chest Pain
Heart Diseases
Nervous System Diseases
Neurologic Manifestations
Pathologic Processes
Signs and Symptoms
Vascular Diseases
Anti-Arrhythmia Agents
Cytochrome P-450 CYP1A2 Inhibitors
Cytochrome P-450 CYP2C9 Inhibitors
Cytochrome P-450 CYP2D6 Inhibitors
Cytochrome P-450 CYP3A Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors
Membrane Transport Modulators processed this record on May 26, 2016